As of November 20, 2020

Internal Selection Competitions

*NEW* US Enhanced Surveillance Network to Assess Burden, Natural History, and Effectiveness of Vaccines to Prevent Enteric and Respiratory Viruses in Children (RFA-IP-21-002) (WUSTL Key required) Internal Selection deadline is 12/07/2020 (OPEN); Applications due to CDC 02/8/2021; LOIs due to CDC 01/7/2021.

CDC Conducting Research to Inform Pandemic Response and Recovery of Emergency-Affected Populations by Determining Public Health Needs, Improving Methods, and Integrating Services (RFA-GH-21-004) (WUSTL Key required) Internal Selection deadline is 12/07/2020 (OPEN); Applications due to CDC 02/18/2020; LOIs due to CDC 01/18/2021.

HRSA National Telehealth Resource Center program (HRSA-21-023) (WUSTL Key required) Internal Selection deadline is 11/12/2020 (OPEN); Applications due to HRSA 01/21/2021.

HRSA Regional Telehealth Resource Center Program(HRSA-21-022) (WUSTL Key required) Internal Selection deadline is 11/12/2020 (OPEN); Applications due to HRSA 01/21/2021.

HRSA Rural Health Clinic Technical Assistance Program (WUSTL Key required) Internal Selection deadline is 11/12/2020 (OPEN); Applications due to HRSA 01/21/2021.

Opportunities for Current NIH Funded Researchers (Competitive Revisions & Supplements)

See examples of NIH Administrative Supplements in Box (WUSTL Key required)

*NEW* Notice of Special Interest: Promoting Health, Safety, and Recovery Training for COVID-19 Essential Workers and their Communities(NOT-ES-21-002)
Expiration date is December 30, 2020

  • The purpose of this supplement is to provide support for successful applicants to develop partnerships with local worker centers and community organizations specifically targeting under served and disadvantaged communities with higher than average COVID-19 transmission rates.
  • Components of a COVID-19 Recovery Centers for essential workers should include all of the following highly recommended components. Additionally, the optional components may be added on but are not required.
  • Highly Recommended Components:
    • Local health and safety education and training delivery (classroom and online) using effective infection control plans and adult learning methods to include literacy and English as a second language, population education techniques, as well as multi-lingual training to increase the education and awareness of COVID-19 health risks and protective measures
    • Partnership between a WTP grantee and at least one local community organization that supports outreach to one or more populations vulnerable to COVID-19
    • Integration of existing NIEHS WTP tools, resources, and curricula into training
    • Available sourcing and distribution point of needed personal protective equipment (masks, respirators, face shields, etc.)
    • Coordination with local disaster preparedness, response, and recovery resources to assist vulnerable communities in connecting with the emergency response and recovery process
    • Assessment of program impact and effectiveness to help evaluate how local partnerships with essential workers organizations can help with COVID-19 community recovery
    • IT Technical Assistance and best practices and data integration with virtual learning
    • Appropriate partnership for the proposed project, such as with local public health agencies and area employers, to facilitate connectedness to resources such as testing, contact tracing, and the adoption of effective infection control measures.

Limited Competition Emergency Awards: Shared Personal Protective Equipment Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies (S10 Clinical Trial Not Allowed) (PAR-20-256)

  • The purpose of this public health emergency funding opportunity is to provide Personal Protective Equipment (PPE) to directly support the needs of the NIAID’s vaccine and treatment clinical trials and clinical studies for COVID-19. This program will ensure that adequate protective equipment is available to directly assist in safely carrying out the clinical activities and direct interactions with the patients participating in the trial. Eligibility is limited to recipients conducting COVID-related clinical research and clinical studies supported by NIAID’s emergency appropriation provided by “The Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020” and “The Coronavirus Aid, Relief and Economic Security (CARES) Act”.
  • Applications accepted on a rolling basis.
  • NIAID intends to commit up to $25M for this initiative. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Notice of Special Interest (NOSI): Simulation Modeling and Systems Science to Address Health Disparities (NOT-MD-20-025)
Expiration date is 5/8/2023; First available due date is 10/05/2020

  • Research Objectives:
    • Foster trans-disciplinary partnerships and collaborations in understanding the etiology and causal pathways of health disparities using SMSS
    • Use SMSS to identify modifiable barriers and cost-effective factors to reduce and eventually eliminate health disparities
    • Use SMSS to improve patient safety and reduce medical errors for populations affected by health disparities
    • Use SMSS to assess and predict the spread and consequences of pandemics (e.g., SARS-CoV-2) and the effectiveness of interventions in populations affected by health disparities
    • Provide evidence-based simulation or prediction of the impact of effective or ineffective health disparities interventions delivered in real-world settings
    • Promote big data harmonization and novel analytic methods in SMSS to address minority health and health disparities
  • Research Methodology
    • Examples of research methods could include but are not limited to:
    • System dynamics modeling
    • Network Analysis
    • Agent-based modeling
    • Dynamic microsimulation modeling
    • Discrete event simulation
    • Markov modeling
    • Hybrid simulation modeling (e.g., sequential design, enrichment design, integration design, and parallel design)
  • Research Topics: Applications should be relevant to the objectives of the funding opportunity announcement and to at least one of the participating institutes’ and offices’ research interests. Researchers are strongly encouraged to review the general research interests of the participating ICs.

Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions for Chemosensory Testing as a COVID-19 Screening Tool (NOT-OD-20-152)
Due date is September 1, 2020

  • NIH is issuing this NOSI in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This emergency NOSI from the National Institutes of Health (NIH) provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. The goal of the RADx-rad initiative is to encourage the development of novel, non-traditional approaches to identify the current SARS-CoV-2 virus or other markers of the COVID-19 disease that can be used in future outbreaks of COVID-19 and that could be applicable to other, as yet unknown, viruses. Specifically, the goal of this NOSI is to solicit proposals to enhance the utility of chemosensory testing as a COVID-19 screening tool by using objective tests to examine the onset and prognostic value of chemosensory loss and to encourage the development and/or deployment of home-based and on-site chemosensory tests. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Select Research Activities related to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (NOT-AI-20-059)
Notice expires on 7/2/21

  • NIAID is allowing the submission of applications for Competitive Revisions to active grants to increase and enhance select research efforts to facilitate the Federal SARS-CoV-2/COVID-19 research response. Areas of interest are limited to:
    • Support to BSL3 facilities actively engaged in the SARS-CoV-2/COVID-19 research response, e.g., equipment sharing arrangements. Applications proposing new construction, alterations and renovations for planned and active BSL3 facilities are not responsive to this NOSI;
    • Generation of critical reagents to support the SARS-CoV-2/COVID-19 research response;
    • Expansion of relevant data systems to expeditiously share SARS-CoV-2/COVID-19 research resources with the broad research community; and
    • Expansion of clinical trial infrastructure, or site preparation, for urgent SARS-CoV-2/COVID-19 clinical trial activities. Applications proposing clinical trials are not responsive to this NOSI.

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19) in Individuals with Down Syndrome for the INCLUDE Project
Application Due Dates are 11/12/20, 3/12/21, or 7/12/21

  • This NOSI highlights the urgent need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) in individuals with Down syndrome in conjunction with the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Project. The overarching goal of this NOSI is to improve understanding and treatment of COVID-19 infection in individuals with Down syndrome and reduce COVID-19 associated morbidity and mortality for this population, which may be disproportionately affected by, have higher infection rates of, and/or be at elevated risk for adverse outcomes from contracting the virus.

Notice of Special Interest (NOSI): Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19
Applications will be accepted on a rolling basis from June 10, 2020 through December 15, 2020. Applications submitted before July 15, 2020 will be considered for funding in in Fiscal Year 2020

  • The purpose of this NOSI is to support research to address secondary health effects of the social, behavioral, and economic changes, particularly among populations who experience health disparities and vulnerable populations through the use of digital health assessments and interventions to yield measurable near-term impact. Administrative supplements and competitive revisions applications are expected to describe how research outcomes will lead to a tangible difference within 6 months to a year of completing the supplement work, with respect to improving how we identify, treat, or provide services for health conditions secondary to the COVID-19 pandemic for health disparate and vulnerable populations. 

Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements for Coronavirus Disease 2019 (COVID-19) Research within the Mission of NIDCR (NOT-DE-20-022)
Application due date: November 2, 2020

  • NIDCR will place a high priority on topics that would be of immediate and high impact to protect and ensure the safety of personnel and patients in dental practices.  New knowledge about SARS-CoV-2 transmissibility, stability on surfaces, viral particle size, and presence in saliva have catalyzed a need to consider how the practice of dentistry will be performed in the near and long-term future.

Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions on Coronavirus Disease 2019 (COVID-19) for Currently Active NHLBI Phase I-III Clinical Trials (NOT-HL-20-782)
Expires 10/6/20

  • NHLBI seeks to leverage existing clinical trials expertise and, using NHLBI programs that are actively conducting Phase I-III clinical trials, to rapidly initiate and conduct Phase I-Phase I/II (bridging) clinical trials in patients at risk for SARS-CoV-2 infection and/or patients with COVID-19. It is strongly recommended that the parent activity code be one of the following: P01, R01, R33, R41, R42, R43, R44, U01, U24, U54, UH3, or UM1.

Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements For Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System
(NOT-NS-20-051)

Expires 4/15/21

  • NINDS is encouraging the submission of competitive revision or administrative supplement applications for supplements to address the biology, pathophysiology, prevention, diagnosis, sequelae, or treatment of the 2019 Novel Coronavirus that are directly related to the NINDS mission.

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences (NOT-OD-20-097)
Applications will be accepted on a rolling basis through 3/31/21

  • OBSSR, NHLBI, NIA, NIAAA, NIDDK, NIEHS, NCCIH, NCI, and ORWH encourage submission of applications for urgent competitive revisions or administrative supplements to active grants studying existing longitudinal cohorts, particularly those cohorts with considerable data relevant to COVID-19 social and behavioral factors prior and subsequent to the SAR-CoV-2 outbreak in various locations. Submissions are encouraged to consider four areas: public health mitigation efforts; economic, social and personnel well-being; misinformation being communicated; downstream health effects from economic and social impacts.

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Mental Health Research on the 2019 Novel Coronavirus (NOT-MH-20-047)
Applications accepted on a rolling basis until 4/15/21

  • NIMH, NIA, NIAAA, and NIMHD are accepting applications for supplements and revisions to active projects that significantly improve our understanding of the risks, mechanisms, and treatment in response to COVID-19 among individuals at risk for, or experiencing mental disorders across the full lifespan. This includes but is not limited to, individuals with Mild Cognitive Impairment (MCI), Alzheimer’s disease and Alzheimer’s disease related dementias (AD/ADRD) and their healthcare providers and caregivers.

Notice of Special Interest (NOSI): Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities (NOT-MD-20-019)
Applications accepted on a rolling basis until 5/1/21

  • NIMH, NIA, and NIMHD are accepting applications for supplements and revisions to active projects. This NOSI is soliciting research in health disparity populations that -seeks to understand: 1) how state and local policies and initiatives mitigate or exacerbate disparities in health services use and health outcomes; 2) the role that community-level protective and resilience factors and interventions have in mitigating the effects of the sector disruptions that the COVID-19 outbreak causes; and 3) how behavioral and/or biological mechanisms may contribute to COVID-19 manifestations.

Notice of Special Interest (NOSI): Availability of Administrative Supplements and Urgent Competitive Revisions for Research on Stress Management in Relation to Coronavirus Disease 2019 (COVID-19) (NOT-AT-20-011)
Applications accepted on a rolling basis through 10/6/20

  • NCCIH, NIA, and NIAAA are accepting applications for supplements and revisions to active projects. Topics of specific interest for this NOSI include research on stress management strategies, including mind and body approaches,that individuals may engage in remotely to address stressors related to social distancing, as well as to address recovery and recurrence of symptoms during and after COVID-19 infections.

Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19) (NOT-ES-20-015 / PA-20-135)
Applications are accepted the first week of each month. See Notice for specific dates. (Notice expires on 5/4/21)

  • NIEHS is particularly interested in applications that will provide insight into the role of environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and intervention strategies. NIEHS is accepting applications addressing COVID-19 through the urgent competitive revision, and time-sensitive mechanisms (see Application Information below).

Notice of Special Interest (NOSI): Availability of Emergency Competitive Revision and Administrative Supplements on Biomedical Technologies for Coronavirus Disease 2019 (COVID-19) (NOT-EB-20-008)
Applications accepted on a rolling basis through 11/10/20

  • The NIBIB is seeking applications from current grantees to develop life-saving technologies that can be ready for commercialization within one to two years.

Notice of Special Interest (NOSI): NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19) (NOT-AG-20-022)
Applications will be accepted on a rolling basis from April 6, 2020 through May 1, 2021

  • In order to rapidly improve our understanding and available control measures for 2019-nCoV, NIA is encouraging the submission of applications for either Administrative Supplements (PA-18-591) or Competitive Revisions (PA-18-935) to active grants to address multiple areas of interest within the mission of NIA.

NIDA Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (NOT-DA-20-047)
Applications will be accepted on a rolling basis through 3/31/21

  • NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders. Applications must be submitted using the following funding opportunities: PA-18-935, which is intended to provide funds for NIH grantees applying to expand the scope of their active grant, or PA-18-591, which is intended to provide funds for NIH grantees where the work proposed in the supplement is fully within the scope of the ongoing grant.

NIGMS Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2 (NOT-GM-20-025)
Applications will be accepted on a rolling basis until 2/5/21

  • NIGMS will accept the submission of applications to address incorporation of data related to SARS-CoV-2 into ongoing research efforts to develop predictive models for the spread of SARS-CoV-2 and other related infectious agents (all relevant grants), repurpose/modify diagnostics tools for rapid detection (SBIR/STTR only) and development of therapeutics (SBIR/STTR only).  Applications must be submitted to PA-18-935 which is intended to provide funds for NIH grantees applying to expand the scope of their active grant.

NIAID Notice of Special Interest (NOSI): Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (NOT-AI-20-031)
Application due dates depend on grant mechanism (Notice expires on 4/5/21)

  • National Institute of Allergy and Infectious Diseases (NIAID) is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19. Applications may be submitted as administrative supplements (PA-18-591) to existing awards.

Clinical and Translational Science Awards Limited Funding Opportunities

Notice of Special Interest (NOSI): New Administrative Supplement Applications to UL1 and U24 CTSA Awards to Address COVID-19 Public Heath Need
Applications will be accepted immediately and on a rolling basis through November 10, 2020

  • Encouraging supplement proposals to support the NCATS National COVID Cohort Collaborative (N3C): Provision of clinical data in specified formats to support illness/infection status/surveillance determinations and/or clinical study data (awards anticipated to be $50,000 to $100,000 Total Costs)

Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions and Administrative Supplements to Clinical and Translational Science Award (CTSA) Program Awards to Address 2019 Novel Coronavirus Disease (COVID-19) Public Health Needs
Applications will be accepted immediately and on a rolling basis through November 10, 2020

Notice of Special Interest (NOSI): Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Heath Need
Application due dates depend on grant mechanisms

NIH Funding Opportunities (New Applications)

Notice of Special Interest: Effects of smoking and vaping on the risk and outcome of COVID-19 infection (NOT-DA-20-084)

Expiration date is September 8, 2024; First Available Due Date is January 4, 2021

  • The purpose of this notice is to communicate NIDA’s interest in supporting research on the effects of smoking or vaping tobacco or marijuana on the risk of acquiring COVID-19 and the clinical course of the infection.
  • Research Objectives: NIDA is interested in receiving research applications focusing on individuals who smoke or vape either marijuana and/or tobacco to determine: 1) the risk of contracting a COVID-19 infection, 2) the effects on asymptomatic COVID-19 infected persons, and 3) the course of the COVID-19 infection.
  • This NOSI encourages research to understand:
    • The risks that smoking or vaping tobacco or marijuana may have on acquiring the COVID-19 infection.               
    • The medical consequences, co-morbidity, and complications of COVID-19 infection in individuals who smoke or vape tobacco or marijuana.
    • The medical consequences of COVID-19 in individuals who smoke and vape with comorbid conditions such as: SUD, HIV and other immunosuppressive diseases, mental health disorders, diabetes mellitus, obesity, cardiovascular, pulmonary, renal, and hepatic pathologies, as well as cancer.

Notice of Special Interest: Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19) (NOT-TR-21-006)

Expiration Date is March 17, 2021; First Available Due Date is October 30, 2020

  • National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel coronavirus (SARS-CoV-2) and the disease it causes, i.e., “coronavirus disease 2019” (COVID-19). NCATS is particularly interested in projects that repurpose existing drugs or biologics (existing therapeutics) that have already begun or completed a Phase I clinical trial.
  • The hypothesis for proposed studies must be developed using innovative processes to identify the therapeutic/indication pair. Examples include the following:
    • Testing a publicly posted therapeutic candidate for use to treat COVID-19. Examples include clinical candidate therapeutics in documents publicly posted by the World Health Organization (types/classes of candidate therapeutics) and (candidates for clinical evaluation).
    • Testing a candidate therapy to treat COVID-19 that was already identified with a publicly available computational approach.
    • Testing of existing therapeutic candidates that work on mechanistic targets shared among other viruses that may be relevant to SARS-CoV-2.

NCATS is soliciting applications to PAR-17-465, PAR-18-462, and PAR-18-332.

Notice of Special Interest: Research on Rehabilitation Needs Associated with the COVID-19 Pandemic (NOT-HD-20-031)

Expiration date is May 8, 2023; First Available Due Date: February 05, 2021

  • This NOSI invites research applications on the rehabilitation needs of COVID-19 survivors. At present, the best acute rehabilitation plan for people who have recovered from severe cases of COVID- 19 is unknown. Similarly, the long-term rehabilitation needs and sequalae of people who recover from COVID-19 are not well understood. Furthermore, the interplay of existing physical disabilities and recovery from COVID-19 is also unknown.
  • Research applications are also sought to understand the impact of disruptions to rehabilitation services caused by the COVID-19 pandemic and associated mitigation actions. Applications that measure the impact of delayed treatment for common disabling conditions, such as stroke, are also sought.
  • Finally, research applications investigating the social, behavioral, and economic impact of COVID-19 on people with physical disabilities and their caregivers are requested.
  • Topics of interest include but are not limited to:
    • New clinical trials of acute, chronic, home, and community-based rehabilitation interventions (types, dosing, timing, and intensity) for survivors of severe COVID-19 (e.g. with lung involvement, neurological symptoms, or muscle wasting)
    • EHR analysis of rehabilitation services associated with COVID-19 treatment
    • Physical, social, economic, and health outcomes for patients who receive COVID-19 rehabilitation
    • Studies of how pandemic containment and mitigation actions, such as social distancing requirements, affect the care and well-being of people with disabilities and their caregivers
    • Studies focused on addressing the unique needs of formal and informal caregivers in assisting/supporting survivors of COVID-19 use new methods of rehabilitation delivery during the pandemic
    • Studies of how social distancing guidelines and requirements are implemented and impact people with disabilities in institutions, group settings, and other non-traditional settings
    • Studies examining the impact of healthcare-related stigma, discrimination, harassment, and/or refusal of care on seeking COVID-related healthcare for people with disabilities
    • Development and testing of new methods for delivery of rehabilitation in the home. Target patient groups include both people requiring rehabilitation following COVID-19 as well as typical rehabilitation patients
    • Development and testing of novel metrics of function for use in the home environment with emphasis on the use of mobile or digital devices

Health Services Research on Minority Health and Health Disparities (R01 – Clinical Trial Optional) PAR-20-310

Application Due Dates: November 27, 2020; March 17, 2021; November 17, 2021; March 17, 2022; November 17 2022; February 17, 2023. Expiration Date is March 28, 2023.

  • The purpose of this Funding Opportunity Announcement (FOA) is to encourage innovative health services research that can directly and demonstrably contribute to the improvement of minority health and/or the reduction of health disparities at the health care system-level as well as within clinical settings.
  • Examples of research methods could include, but are not limited to:
    • Cluster-randomized, randomized or practical clinical trials of the effectiveness of new or existing technologies (e.g., telehealth), non-technological interventions, and multi-level interventions that involve broad inclusion of patients from health disparity populations and addresses a disease or condition that disproportionately impacts health disparity populations (e.g., infectious diseases such as COVID-19, chronic diseases such as cancer, diabetes, cardiovascular conditions, asthma, and others, mental health/substance abuse disorders including perinatal depression, and maternal and infant mortality).
  • Research topics of interest include but are not limited to:
    • Studies on the effects of emerging infectious diseases such as the COVID-19 pandemic on disparities in health care utilization and health outcomes among medically vulnerable populations such as institutionalized and non-institutionalized older adults; persons with chronic conditions, mental health and/or substance abuse disorders, complex medical needs, and/or with compromised immune system function; and pregnant women. In addition, examine the effects of these infectious diseases on disparities in health care utilization and health outcomes among socially vulnerable populations such as the homeless, the recently incarcerated, immigrants, persons with disabilities, and children.
    • Studies on the effects of the COVID-19 pandemic on disparities in access to care and quality of care for health disparity populations, taking into account how it impacts the structure and organization of different health care systems that serve health disparity populations, including those living in rural areas.
    • Research to examine the role of federal, state and local policies in different sectors (e.g., health care, labor, transportation, housing) in exacerbating or reducing the impact of the COVID-19 pandemic, chronic medical conditions, or other diseases that have disproportionate effects on minority health and health disparities.
    • Studies of clinical procedures or guidelines into existing care systems such clinician or health care system decision-making about advanced ventilatory support for patients with severe advanced COVID-19 or other acute severe diseases with high mortality.

Notice of Special Interest: Emerging Viral Infections and their Impact on the Male and Female Reproductive Tract (NOT-HD-20-021)
Expiration date is 07/16/2023; First Available due date is 10/05/2020.

  • The purpose of this Notice is to invite applications proposing cutting-edge research on emerging viral infections that are thought to primarily impact non-reproductive sites, at least at initial presentation, but may also affect the male and/or female reproductive tract. The recent global outbreak of the novel coronavirus, SARS-CoV-2, is not an anomaly and will most likely not be the last virus occurrence. Today, infectious diseases are emerging and reemerging more quickly than ever before. In the last four-five years alone, two viral infections, one caused by the Zika virus (ZIKV) and the other caused by a SARS-CoV-2 (Covid19), have spread world-wide, resulting in death, severe disease with yet, unknown, long-term morbidities., or severe birth defects to the new-born. Both ZIKV and SARS-CoV-2 infections may affect male and/or female reproductive systems in addition to other non-reproductive sites. Therefore, it becomes essential to investigate possible effects of emerging viruses on reproductive tissues and cells to better understand potential impacts on fertility that may be sex specific.
  • Currently, knowledge gaps exist in our understanding of viral infections of both male and female reproductive tract tissues. This NOSI is interested in the recently emergent ZIKA and novel corona viruses, as well as other yet unidentified viruses which may significantly impact public health. Areas of interest of this NOSI include, but are not limited to:
    • Consequences of infection, e.g., cells affected and outcomes of infection – infertility, miscarriage, live births, orchitis, epididymitis, pelvic pain;
    • Mechanism of action for infectivity of reproductive tract tissues;
    • Mechanism of sexual transmission;
    • Whether the reproductive tract acts as a reservoir for viruses;
    • Sex-specific differences in infection as they may relate to reproductive tract tissues and cells;
    • The impact of race and ethnicity on reproductive system impacts of viruses;
    • Impact of nutrition, e.g., Vitamin D sufficiency and the understanding of mechanisms that explain the impact of obesity;
    • Development of model systems to study infections in reproductive tract tissues, e.g., organoids (for R21 applications only)
  • Non-responsive applications:
    • Infections exclusively localized to the reproductive tract, e.g., urinary tract infections, chlamydia, HPV, HSV, hepatitis B;
    • Epidemiological analysis of a particular infection.

Notice of Special Interest (NOSI): Availability of Emergency Awards for Limited Clinical Trials to Evaluate Therapeutic and Vaccine Candidates Against SARS-CoV-2
Expiration date is 9/1/2021; First Available due date is 9/01/2020

  • This Notice of Special Interest encourages cooperative agreement applications for implementation of investigator-initiated high-risk clinical trials, as defined by NIAID in PAR-18-633 and NOT-AI-16-084, that will augment ongoing and planned clinical trials of therapeutic and vaccine candidates directed against SARS-CoV-2 to evaluate:
    • SARS-CoV-2 candidate vaccines
    • non-vaccine biomedical prevention of SARS-CoV-2 infection and/or COVID-19
    • therapeutic approaches to treat COVID-19
  • Please note, studies evaluating behavioral interventions (e.g., impact of face masks, hand- washing, social distancing) and those focused on disinfecting surfaces and equipment are not responsive and will not be considered for this NOSI initiative.
  • Investigators interested in responding to this NOSI are strongly encouraged to submit a written request for prior consultation to the email address listed below prior to submission of an NIAID Clinical Trial Implementation (U01) Cooperative Agreement application in response to PAR-18-633 to discuss the proposed project in the context of the needs identified above. This request should be as succinct as possible and include the study title and a brief description of the study and product to be evaluated; study PI; primary institution and potential collaborating sites; industry partners, if applicable; and a cost estimate. As a reminder, per NIH policy, applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact NIAID staff listed below no later than 6 weeks before submission and follow the Policy on the Acceptance for Review of Unsolicited Applications that Request $500,000 or More in Direct Costs as described in the SF424 (R&R) Application Guide.

Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) (PAR-20-238)
Application due dates: May 17, 2021, May 17, 2022, May 17, 2023

  • The purpose of this funding opportunity announcement (FOA) is to support research on interventions to improve health in Native American (NA) populations. This includes 1) etiologic research, where there is a significant gap in knowledge, that will directly inform intervention development or adaptations, 2) research that develops, adapts, or tests the efficacy or effectiveness of health promotion and disease prevention interventions, 3) research that tests culturally informed treatment or recovery interventions and 4) where a sufficient body of knowledge on intervention efficacy exists, research on dissemination and implementation that develops and tests strategies to overcome barriers to the adoption, integration, scale-up, and sustainability of effective interventions. Existing data suggest that significant acute and chronic disease inequities exist for NA populations.  Concurrently, NA populations experience unique sociopolitical, historical, and environmental stressors and risks that may exacerbate health conditions and/or impact the effectiveness of existing solutions to address the conditions. They also possess unique strengths and resiliencies that can mitigate stressors or inform intervention strategies. Through this initiative, intervention and related research is sought to build upon community knowledge, resources, and resilience to test science-based, culturally appropriate solutions to reduce morbidity and mortality through identification and remediation of precursors to diseases and disorders and through culturally informed treatment.  Interventions should be designed with a consideration for sustainability within the communities where they are tested, and have the flexibility to be readily adapted, disseminated, and scaled up to other communities where culturally appropriate. For the purposes of this FOA, Native Americans include the following populations: Alaska Natives, American Indians (whose ancestral lands fall at least partially within the U.S. mainland border), and Native Hawaiians.  The term ‘Native Hawaiian’ means any individual any of whose ancestors were natives, prior to 1778, of the area which now comprises the State of Hawaii.
  • NHLBI: One of the Examples of projects of interest to NHLBI include the following: Strategies and behavioral interventions that may mitigate the impact of COVID-19 on heart, lung, blood, and sleep diseases and disorders

Notice of Special Interest (NOSI): Comprehensive Care for Adults with Type 2 Diabetes Mellitus from Health Disparity Populations (NOT-MD-20-026)
First Available Due date 10/5/20; Notice expires on 5/8/21

  • The purpose of this Notice of Special Interest is to support multidisciplinary, investigative and collaborative research focused on developing and testing multi-level strategies to effectively implement recommended guidelines of comprehensive clinical care for individuals with Type 2 diabetes from health disparity populations.
    • One example of potential topic areas mentions COVID-19
      • Studies on the multi-level effects of the COVID-19 pandemic and/or their intersection on access to health care services and continuity of care, for example patient level factors (e.g., loss of health insurance due to job loss; impact on self-management due to caregiving and homeschooling responsibilities) health care setting level factors (e.g., changes and rescheduling of services due to policies on physical distancing; medication availability and refills, health care settings strategies and best practices to ensure appropriate and timely care), and societal factors (impact of policies on physical distancing on nutrition, physical activity, and emotional well-being). Costs/economic analyses are of interest.

Urgent Phase I/II Clinical Trials to Repurpose Existing Therapeutic Agents to Treat COVID-19 Sequelae (U01)
Applications will be accepted on a rolling basis, beginning on 8/6/2020

  • The purpose of this urgent funding opportunity announcement is to invite applications to repurpose existing therapeutic agents to treat Coronavirus Disease 2019 (COVID-19) sequelae and associated complications that result from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections. The therapeutic agent must have already completed at least a Phase I clinical trial for a different indication, and not require additional regulatory studies for the new indication prior to starting a clinical trial.

Notice of Intent to Publish a Funding Opportunity Announcement for HEALthy Brain and Child Development Study (NOT-DA-20-069)

  • NIH plans to publish a set of Funding Opportunity Announcements (FOAs) as part of the Helping to End Addiction Long-termSM (HEAL) Initiative to support research project sites, a Data Coordinating Center, and a Consortium Administrative Core for the HEALthy Brain and Child Development (HBCD) Study. The primary objective of the HBCD Project is to conduct a large scale multi-site longitudinal study that can prospectively examine human brain, cognitive, behavioral, social, and emotional development beginning at birth and extending through middle childhood. The FOAs are expected to be published in Fall 2020 with an expected application due date in WINTER 2021.

Mechanistic Studies of the Interaction between SARS-CoV-2/COVID-19 and Diseases and Organ Systems of Interest to NIDDK (R01 Clinical Trial Optional, RFA-DK-20-021)
Applications are due 12/16/20

  • This FOA support basic and clinical mechanistic research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) susceptibility, routes of infection, course of disease, morbidity and mortality in people with pre-existing diseases, or adverse acute or chronic outcomes in organs, tissues, and biological systems of specific interest to NIDDK. 

Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19 (R01 – Clinical Trial Optional)
Applications are due 12/2/20, or 3/2/21

  • Focuses on the role and impact of digital health interventions [e.g., mobile health (mhealth), telemedicine and telehealth, health information technology (IT), and wearable devices] to address access, reach, delivery, effectiveness, scalability and sustainability of health assessments and interventions for secondary effects (e.g., behavioral health or self-management of chronic conditions) that are utilized during and following the pandemic, particularly in populations who experience health disparities and vulnerable populations

Notice of Special Interest (NOSI): Utilizing Telemedicine or Other Remote-Based Platforms to Develop and Support Treatments for Substance Use Disorders
This notice applies to standard R01 and R21 due dates on or after October 5, 2020 and subsequent due dates until 1/8/24.

  • We expect this NOSI to accelerate the development of 1) remotely-delivered SUD treatment interventions, and 2) remote methods for collecting outcome measures evaluating the safety or efficacy of SUD treatments. These advances will facilitate the delivery of effective treatments to those in need and permit the execution of clinical trials when physical access to clinical research sites is limited. Ultimately, both these advances will lead to improved treatment options for individuals with SUD.

NIA Multi-site COVID-19 Related Clinical Trial Implementation Grant on Aging-Related Topics in at-risk Older Adult Populations (R01 Clinical Trial Required)
Applications are due: 11/2/2020, 11/2/,2020, 12/1/2020, 1/4/2021, 2/1/2021

  • Invites applications for implementation of investigator-initiated multi-site clinical trials (all phases or stages) of interventions focused on specific aging-related issues to reducing transmission, risk, morbidity, mortality, severity, or complications of Coronavirus Disease 2019 (COVID-19)

Community Interventions to Address the Consequences of the COVID-19 Pandemic among Health Disparity and Vulnerable Populations (R01- Clinical Trial Optional)
Applications are due: 12/1/20

  • Encourages applications to implement and evaluate community interventions testing 1) the impacts of mitigation strategies to prevent COVID-19 transmission in NIH-designated health disparity populations and other vulnerable groups; and 2) already implemented, new, or adapted interventions to address the adverse psychosocial, behavioral, and socioeconomic consequences of the pandemic on the health of these groups


NIA Multi-site COVID-19 Related Clinical Trial Implementation Grant on Aging-Related Topics in at-risk Older Adult Populations (R01 Clinical Trial Required)
Applications are due November 2, 2020; December 1, 2020; January 4, 2021; and February 1, 2021.

  • This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated multi-site clinical trials (all phases or stages) of interventions focused on specific aging-related issues to reducing transmission, risk, morbidity, mortality, severity, or complications of Coronavirus Disease 2019 (COVID-19). 

Notice of Special Interest (NOSI): NIDCD is Interested in Supporting Research on the Impact of COVID-19 on Mission Specific Sensory and Communication Disorders
This notice applies to due dates on or after October 5, 2020 and subsequent receipt dates through September 8, 2022.

  • NIDCD invites applications for research on COVID-19 in relation to NIDCD’s scientific programs of hearing, balance, taste, smell, voice, speech and language (HBTSVSL). Given the early stage of COVID-19 research, it is critical that there is a strong premise for research proposals submitted in response to this NOSI. When appropriate, NIDCD encourages multi-disciplinary approaches to move the research beyond in vitro and animal models.

RFA-AA-20-009 — Alcohol-HIV/AIDS Program Project Comorbidities, Coinfections, and Complications Research: Intervention and Cross-Cutting Foundational Research (P01 Clinical Trial Optional) 
Applications are due 11/17/20

  • The Funding Opportunity Announcement will solicit applications for human studies that will advance operations or implementation research in the context of alcohol and HIV/AIDS by facilitating the development of: (1) broader systems approaches for monitoring complex HIV and alcohol-related morbidity and mortality, and (2) interventions to reduce the impact of alcohol on HIV disease progression and transmission.  

New COVID-19 priority areas and due dates for PAR-19-373 and PAR-19-384, “Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01)”
Next application due date: 3/17/21

  • These FOAs solicits research projects that seek to model the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in health, illness, recovery, and overall wellbeing. There are new priority topics related to COVID-19 pandemic.

RadX – Tech – NIH POCTRN Fast-Track Program for COVID-19 Test Development and Distribution Innovative Technologies to Increase U.S. Capacity for COVID-19 Testing
Accepting proposals for support on a rolling basis until further notice

  • NIBIB is urgently soliciting proposals and can provide up to $500M across multiple projects to rapidly produce innovative SARS-CoV-2 diagnostic tests that will assist the public’s safe return to normal activities.

Notice of Special Interest (NOSI): Data Driven Research on Coronavirus Disease 2019 (COVID-19) (R21)(NOT-LM-20-011)
National Library of Medicine

  • NLM is accepted new R21 applications on the June 16, 2020 deadline only. NLM is encouraging the submission of R21 applications to address the following research areas of interest: (1) Methods for mining clinical data that can be used to identify or predict presence of COVID-19 in biomedical phenotype data, or other relevant topics such as discovery of risks for infection by SARS-Cov-2 viruses, use of standard terminologies for these viruses in federated health data sets; (2) Public health surveillance methods that mines genomic, viromic, health data, environmental data and/or data from other pertinent sources such as social media, to identify spread and impact of SARS-Cov-2

Long-Term Effects of Disasters on Health Care Systems Serving Health Disparity Populations (R01- Clinical Trial Optional) (PA-20-172)
Standard due dates starting 10/5/20

  • This FOA supports investigative and collaborative research focused on understanding the long-term effects of natural and/or human-made disasters, such as the COVID-19 pandemic, on health care systems serving health disparity populations in communities in the U.S.

Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial Not Allowed) (RFA-ES-19-011 / NOT-ES-20-015)
Applications are accepted the first week of each month. See Notice for specific dates. (Notice expires on 5/4/21)

  • NIEHS is particularly interested in applications that will provide insight into the role of environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and intervention strategies. NIEHS is accepting applications addressing COVID-19 through the urgent competitive revision, and time-sensitive mechanisms (see Application Information below).

Notice of Special Interest (NOSI): Availability of Emergency Competitive Revision and Administrative Supplements on Biomedical Technologies for Coronavirus Disease 2019 (COVID-19) (NOT-EB-20-007)
Application standard due dates apply (Notice expires on 3/31/21)

  • The NIBIB is seeking new R01, R21, and R03 applications to develop life-saving technologies that can be ready for commercialization within one to two years.

Notice of Special Interest (NOSI): Small Business Research and Development of Biomedical Technologies for Coronavirus Disease 2019 (COVID-19) (NOT-EB-20-006)
Standard application due dates apply (Notice expires on 3/31/21)

NIAID Notice of Special Interest (NOSI): Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (NOT-AI-20-031)
Application due dates depend on grant mechanism (Notice expires on 4/5/21)

  • National Institute of Allergy and Infectious Diseases (NIAID) is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19. Applications may be submitted through R03, R21, or R01 mechanisms.

NCATS Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19) (NOT-TR-20-012)
Application due dates vary by mechanism (Notice expires on 10/17/20)

  • National Center for Advancing Translational Sciences (NCATS) is particularly interested in projects that repurpose existing drugs or biologics (existing therapeutics) that have already begun or completed a Phase I clinical trial.  Grant mechanisms include Bench Testing (UG3/UH3), Clinical Trial Planning (U34), or Clinic Testing (U01).

NSF Funding Opportunities & Priorities

NSF Dear Colleague Letter: Request for SBIR/STTR Phase I Proposals Addressing COVID-19  (Funding Opportunity Number: NSF 20-065)
There are four submission windows for Phase I proposals in 2020.

  • The Division of Innovation and Industrial Partnerships (IIP) of the Engineering Directorate invites US-based small businesses to submit Phase I proposals focused on the development and deployment of new technologies, products, processes, and services with the potential to positively impact the nation’s and world’s ability to respond to the COVID-19 crisis

Joint NSF-BSF Programs Dealing with the Coronavirus Disease
Applications may be submitted anytime

  • The U.S.-Israel Binational Science Foundation (BSF) is accepting applications dealing with the Coronavirus Disease in all the active NSF-BSF programs. Applications must be written jointly by an Israeli scientist in an Israeli institution and a U.S. scientist from a U.S. research institution. Proposals should be submitted through the NSF Rapid Response Research (RAPID) funding mechanism. Presently, all biology units of the NSF (BIO), Geosciences, Materials, Physics and CBET divisions are open for submission.

NSF Dear Colleague Letter on the Coronavirus Disease 2019 (COVID-19) (NSF 20-052)
Applications may be submitted anytime

  • NSF is accepting proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge.

NSF Dear Colleague Letter: Provisioning Advanced Cyberinfrastructure to Further Research on the Coronavirus Disease 2019 (COVID-19) (NSF 20-055)
Applications may be submitted anytime

  • The Office of Advanced Cyberinfrastructure (OAC) within the Directorate for Computer and Information Science and Engineering is inviting RAPID proposals and supplemental funding requests to existing awards that address COVID-19 challenges through data and/or software infrastructure development activities.

Centers for Disease Control and Prevention

*NEW* US Enhanced Surveillance Network to Assess Burden, Natural History, and Effectiveness of Vaccines to Prevent Enteric and Respiratory Viruses in Children (RFA-IP-21-002) (WUSTL Key required) Internal Selection deadline is 12/07/2020 (OPEN); Applications due to CDC 02/8/2021; LOIs due to CDC 01/7/2021.

  • The goal of this Notice of Funding Opportunity (NOFO) is to support a network of US  institutions to develop and implement standard research protocols to conduct prospective active surveillance for: a) acute gastroenteritis (AGE) due to norovirus, rotavirus and other enteric viruses; b) acute respiratory illnesses (ARI) due to respiratory viruses including, but not limited to, influenza, RSV, parainfluenza viruses, human metapneumovirus, rhinoviruses, enteroviruses (including EV-D68), adenoviruses, and coronaviruses (including SARS-CoV-2); and c) acute flaccid myelitis (AFM) syndrome and multisystem inflammatory syndrome in children (MIS-C) among pediatric patients seeking healthcare at medical institutions. The network should also provide accurate estimates of the effectiveness in this population of influenza, rotavirus, COVID-19 and other vaccines against respiratory or enteric virus-associated illnesses projected to become available during the period of performance (e.g., RSV, norovirus). Participating institutions should identify AGE, ARI, AFM and MIS-C illnesses among pediatric patients seeking healthcare or diagnostic testing for acute illness in inpatient, outpatient and emergency departments. Recipients should enroll patients meeting standard symptom criteria, and confirm viral infection using approved molecular assays. Vaccine effectiveness (VE) estimates will be calculated. Estimates of VE, burden of disease, and information on the natural history of disease will be used to: a) inform best practices for diagnosis and treatment protocols; b) inform vaccine recommendations; and c) assess public health impact of vaccination and public health programs to prevent viral illness-related healthcare encounters and medical visits among pediatric populations.
  • The estimated total funding (direct and indirect) for the first year (12-month budget period) is $13,650,000 with individual awards estimated to range from $1,600,000 to $1,950,000 for all components combined. The estimated total funding (direct and indirect) for the entire project period is $68,250,000. The project period is anticipated to run from 09/01/2021 to 08/31/2026.

CDC Conducting Research to Inform Pandemic Response and Recovery of Emergency-Affected Populations by Determining Public Health Needs, Improving Methods, and Integrating Services (RFA-GH-21-004) (WUSTL Key required) Internal Selection deadline is 12/07/2020 (OPEN); Applications due to CDC 02/18/2021; LOIs due to CDC 01/18/2021.

  • The purpose of this NOFO is to understand the needs of emergency-affected and displaced populations and estimate morbidity and mortality in the context of the COVID-19 pandemic. The overall goals of this operational research are to a) improve mortality and cause of death estimation during the acute emergency phase, b) understand COVID-19 disease transmission, contributing factors and secondary health consequences, c) study the effects of various hand hygiene interventions on mitigating the spread of COVID-19 and d) understand the mental health impact of COVID-19 to reduce associated morbidity and mortality among displaced populations and in emergency settings.
  • The estimated total funding available including direct and indirect costs, for the entire 5-year project period is $75M. The number of awards will be up to 5.

Emerging Infections Network – Research for Preventing, Detecting, and Managing Travelers who Acquire Infectious Disease Abroad (RFA-CK-21-002)

Application Due Date: 12/18/2020

  • The purpose of this notice of funding opportunity (NOFO) is to support research activities that will assist with the prevention, detection, and management of international travelers who become ill during or after travel. The project must have a focus on travel and tropical medicine providers with the capability to participate in both research and surveillance to determine the disease prevention strategies, burden, severity, optimal diagnostics, treatment interventions, and outcomes of infectious diseases acquired by travelers while abroad. This research will bridge the gap between clinical medicine and public health by assisting with improving patient care, better understanding the natural history of disease, and implementing optimal diagnostic and treatment strategies, with the ultimate outcome being an advancement in the global health security of the United States.
  • Mechanism of Support: U01 – Research Project – Cooperative Agreement
  • Funds Available and Anticipated Number of Awards: The estimated total funding available, including direct and indirect costs, for the entire five (5)-year project period is $7,500,000. The number of awards is estimated to be one (1). Awards issued under this NOFO are contingent  upon availability of funds and a sufficient number of meritorious applications. Because the nature and scope of the proposed research will vary from application to application, it is also  anticipated that the size and duration of each award may also vary. The total amount awarded and the number of awards will depend upon the number, quality, duration and cost of the  applications received.
  • Budget and Project Period: The estimated total funding (direct and indirect) for the first year (12-month budget period) is $1,500,000 with individual awards ranging from $1,000,000 to $1,500,000 for the first year. The estimated total funding (direct and indirect) for the entire  project period is $7,500,000. The project period is anticipated to run from 09/01/2021 to  8/31/2026.

Department of Defense

DARPA Young Faculty Award (YFA)

Closing Date for Applications: January 8, 2021

  • The Defense Advanced Research Projects Agency (DARPA) Young Faculty Award (YFA) program aims to identify and engage rising stars in junior faculty positions in academia and equivalent positions at non-profit research institutions and expose them to Department of Defense (DoD) and National Security challenges and needs. In particular, YFA will provide high-impact funding to elite researchers early in their careers to develop innovative new research directions in the context of enabling transformative DoD capabilities. The long-term goal of the program is to develop the next generation of scientists and engineers in the research community who will focus a significant portion of their future careers on DoD and National Security issues. DARPA is particularly interested in identifying outstanding researchers who have previously not been performers on DARPA programs, but the program is open to all qualified applicants with innovative research ideas.
  • Before preparing an executive summary or proposal submission, proposers are encouraged to review the DARPA mission statement and current program descriptions at the DARPA website to familiarize themselves with examples of current DARPA investments. This is not meant as instruction to duplicate those efforts, but rather to illustrate that current programs are aimed at research that will substantially advance our capabilities in these areas. Once awards are made, each YFA performer will be assigned a DARPA Program Manager with interests closely related to their research topic. The Program Manager will act as project manager and mentor to the YFA award recipients.
  • This RA seeks grant proposals for a research activity consisting of a 24-month base period. No award type other than grants will be issued under this RA. Each 12-month interval of the base period shall not exceed $250,000. Proposals should also include a 12-month option period with a maximum funding level of $500,000. The 12-month option period, referred to as the “Director’s Fellowship,” will be reserved for a limited number of awardees who demonstrate exceptional YFA project performance over the 24-month base period. A target start date of July 2021 may be assumed for planning purposes.
  • This RA solicits single principal investigator (PI) proposals for research and development in the specific TAs of interest articulated below. Prior to submitting a full proposal, proposers are strongly encouraged to first submit an executive summary as described in Section IV. At the executive summary phase, proposing PIs are limited to one executive summary per TA; at the full proposal phase, proposing PIs are limited to submitting only one full proposal to only one topic under this RA. Submitting more than one full proposal may result in all of the PI’s proposal submissions being determined non-conforming and being removed from award consideration. Potential applicants are encouraged to carefully consider the descriptions of the TAs before submission. Each submission (executive summary or full proposal) must specify ONE and only one TA for the submission and identify this TA on the submission’s cover sheet. Executive Summaries and Full Proposals (limit of one proposal per proposer) that do not clearly address a specific topic may be deemed non-conforming and may not be reviewed. DARPA reserves the right to assign a proposal or an executive summary to a different topic area than indicated by the proposer.
  • The TA (#2 out of 27) that mentions COVID-19
    Infectious Disease Detection of Individuals at Facility Ingress
    • Current intake methods for individuals entering into DoD or civilian medical installations rely on patient self-report and memory regarding medical and travel history and current symptomology. These data do not facilitate early warning to medical practitioners. Standard of care for remote detection of illness is limited to temperature measurements obtained via emitted infrared radiation. A need exists for technological solutions to rapidly and remotely (~ <20m) assess incoming individuals in order to detect their infection status.
  • In order to address this issue, DARPA is seeking proposals to investigate technological approaches for understanding signatures of infectious disease within individuals, whether symptomatic or not. The specific aims of the work will be to explore novel methods of standoff disease detection by characterizing the specific attributes, or phenomena, indicative of an individual’s infection status. Diseases/pathogens of interest are primarily respiratory illnesses such as COVID-19 (SARS-CoV-2) and Influenza A/B. Supported research will be in the areas of remote inspection of signatures via waveform interaction technologies (e.g., optical, RF, IR, Raman, frequency combs, acoustic, quantum, etc.). Such research will determine whether signature profiles consistent with infection status exist for both symptomatic and asymptomatic individuals and that such profiles can be ascertained via standoff detection. If such signatures exist, it is critical to understand how they change in the presence of confounders such as environmental temperature, clothing, individual demographics, and physical characteristics. Proposals must include a detailed description of the specific hypotheses to be tested, the envisioned use cases, and justification for technical feasibility.

Department of Energy/Private Sector

COVID-19 High Performance Computing (HPC) Consortium Request for Proposals
Applications may be submitted anytime

  • The COVID-19 High Performance Computing Consortium is a unique private-public effort to bring together federal government, industry, and academic leaders who are volunteering free compute time and resources on their world-class machines. Researchers are invited to submit COVID-19 related research proposals to the consortium, which will then be reviewed for matching with computing resources from one of the partner institutions.

Health Resources and Services Administration (HRSA)

HRSA Regional Telehealth Resource Center Program(HRSA-21-022) (WUSTL Key required) Internal Selection deadline is 11/12/2020 (OPEN); Applications due to HRSA 01/21/2021.

  • This notice announces the opportunity to apply for funding under the Regional Telehealth Resource Center (RTRC) Program. RTRCs assist health care organizations, health care networks, and health care providers in the implementation of cost-effective telehealth programs to serve rural areas and populations. RTRCs also assist patients and families living in rural areas with telehealth technology to obtain health services. This notice of funding opportunity (NOFO) will support 12 RTRCs that focus on statewide and regional telehealth activities as shown below. RTRCs will serve as focal points for advancing the effective use of telehealth technologies in their respective communities and states.
  • Estimated Total Program Funding: $3,900,000. Award Ceiling is $325,000. 

HRSA Rural Health Clinic Technical Assistance Program (WUSTL Key required) Internal Selection deadline is 11/12/2020 (OPEN); Applications due to HRSA 01/21/2021.

  • This notice announces the opportunity to apply for funding under the Rural Health Clinic Technical Assistance Program. The purpose of this program is to:
    • Identify key policy issues and knowledge gaps among RHCs about topics including regulatory and program compliance, billing and reimbursement, quality improvement, best practices around disease management and care coordination, and RHC policy priorities;
    • Identify tools, resources and strategies to address policy issues, knowledge gaps and other challenges faced by RHCs; and
    • Inform RHCs and other rural stakeholders about key RHC issues that affect, or have the potential to affect, care delivery.
  • HRSA estimates approximately $100,000 to be available annually to fund one recipient.

HRSA National Telehealth Resource Center program (HRSA-21-023) (WUSTL Key required) Internal Selection deadline is 11/12/2020 (OPEN); Applications due to HRSA 01/21/2021.

  • This notice announces the opportunity to apply for funding under the National Telehealth Resource Center (NTRC) Program. The purpose of NTRCs is to support the delivery of telehealth technical assistance through Regional Telehealth Resource Centers (RTRCs). Two NTRCs may be funded.

On January 31, 2020, the Secretary of the U.S. Department of Health and Human Services declared a public health emergency in response to COVID-19. Should the public health emergency still be in place at the time of this funding notice, and in response to this public health emergency, you may include COVID-19 related activities in your application. Activities could include increased emphasis on support of telehealth directly to consumers or telehealth for public health emergency response. Applicants that focus on such emergency use of telehealth should also outline plans to shift priorities for changing needs and uses of telehealth.

NASA

Making Innovative Use of NASA Satellite Data to Address Environmental, Economic, and/or Societal Impacts of the COVID-19 pandemic
Applications will be accepted on a rolling basis through 3/29/21

  • NASA’s Earth Science Division (ESD) would like to call the attention of the Earth Science research, applications, and data systems communities to Program Element A.28 “Rapid Response and Novel Research in Earth Science” (RRNES) of Research Opportunities in Space and Earth Sciences (ROSES) 2020 as an opportunity to propose investigations making innovative use of NASA satellite data to address regional-to-global environmental, economic, and/or societal impacts of the COVID-19 pandemic.

NIST

NIST Manufacturing USA National Emergency Assistance Program (2020-NIST-MFGUSA-NEAP-01)
Applications will be accepted on rolling basis
(Washington University is not eligible as the lead institution but may participate on an application.)

  • National Institute of Standards and Technology (NIST) invites Manufacturing USA institutes to propose high-impact projects designed to respond to the COVID-19 pandemic.  Projects may include medical countermeasures; non-medical countermeasures; leveraging institute capabilities to strengthen state and community resilience; grants to companies and technical support to accelerate productions of critical materials, equipment, and supplies; creation of additional production facilities; technology roadmapping for pandemic response and recovery; reshoring the manufacture of critical conventional drugs and ensuring supply chain for critical materials related to pandemic response; or workforce development and training for a skilled advanced manufacturing workforce.

USAID

COVID-19 FUNDING REQUESTS AND UNSOLICITED PROPOSALS
Concepts accepted on a rolling basis

  • USAID is responding to the COVID-19 pandemic with decisive action at home and abroad. Our priorities in the COVID-19 response are to protect the safety and health security of our global workforce, ensure that we can continue our life-saving mission across the world, and support partner countries in their response to COVID-19. Partners may submit unsolicited proposals to COVID19_Concepts@usaid.gov.

Non-Federal Opportunities

FSFW Health, Science, and Technology Request for Proposals
Topic: COVID-19, Smoking, and Nicotine Research

  • Applications due December 15, 2020 5 PM UK Greenwich Mean Time
  • Scoping / pre-clinical studies: Up to US$ 150,000 for up to 3 months
  • Epidemiological studies: Up to US$ 250,000 for 3 to 6 months
  • Clinical studies: Up to US$ 500,000 for up to 1 year
  • The Foundation for a Smoke-free World is seeking to conduct research at the nexus of COVID-19, smoking, and nicotine that will require significant collaboration and research efforts with outside experts and organizations. We seek to advance knowledge of value to science and policy in these areas. The selected organization(s) will implement a range of projects relevant to the global pandemic, including well-designed and comprehensive pre-clinical, clinical, and epidemiological studies, to better understand the associations between smoking and / or nicotine use, and COVID-19 infection and outcomes.
  • To address current knowledge gaps, this RFP seeks to accelerate research in the following areas:
    • The impacts of tobacco and nicotine products on COVID-19 outcomes
    • Opportunities for intervention to prevent or reduce COVID-19 infection, hospitalization, and disease progression
    • Interventions to promote healthier lifestyles (including but not restricted to nicotine use) in the wake of the pandemic

Foundation for Women’s Cancer Diversity and Inclusion Health Equity Research Grant

  • Abstract due 09/21/2020; Full proposal due 11/25/2020
  • Research among diverse populations has demonstrated disparities in treatment outcomes, access to care, genetic testing rates, and disease survival across many diseases. This new Diversity and Health Equity Research Grant is a one-year project where the funding is available for two $75,000 Research grants.
  • The purpose of this award is to support research to understand and eliminate inequities in cancer care, specifically related to differential outcomes experienced by women from underserved or marginalized populations with gynecologic cancer, as well as to increase representation of underrepresented groups in gynecologic oncology as a strategy to achieve health equity for underserved women. Those eligible for applying are those who propose a study focused on a marginalized group, or those who identify as being from an under-represented group within the field of research.
  • This year priority consideration will be given to proposals addressing health disparities in the context of gynecologic cancers related to the COVID-19 pandemic.

Wellcome, Bill & Melinda Gates Foundation, and Mastercard
The Bill & Melinda Gates Foundation, Wellcome, and Mastercard have committed up to $125 million in seed funding to speed-up the response to the COVID-19 epidemic by identifying, assessing, developing, and scaling-up treatments. The COVID-19 Therapeutics Accelerator will play a catalytic role by accelerating and evaluating new and repurposed drugs and biologics to treat patients with COVID-19 in the immediate term, and other viral pathogens in the longer-term.

Topics: The Accelerator is seeking partners for the following activities:

  • Identifying candidate compounds by testing approved drugs for activity against COVID-19, screening libraries of compounds with confirmed safety data, and considering new investigational compounds and monoclonal antibodies.
  • Developing drugs or monoclonal antibodies that pass initial screening.
  • Scaling up production and commercialization of successful drugs and monoclonal antibodies.

PCORI Phased Large Awards in Comparative Effectiveness Research (PLACER)
LOI applications are due 9/29/2020. Full applications are due 1/12/2021.

  • This PCORI funding announcement invites applications for high-quality comparative effectiveness research (CER) projects that will examine a critical patient-centered research question that is also relevant to decision makers and other stakeholders. For this PFA, investigators should propose an individual-level or cluster randomized controlled trial of significant scale and scope, requiring funding in excess of $10 million in direct costs. The proposed trials should address important decisional dilemmas that require important new evidence about the comparative effectiveness of available interventions.

CISCO Pandemic/COVID19 Science, Technology and Social Impact

  • Cisco is interested in both the science and technology aspects of these problem sets, and, particularly, in the intersections between them. By cultivating stronger partnerships between scientists, technologists, and the broader community; we hope to achieve an acceleration of scientific research and conservation outcomes as we push the boundaries of our technologies and architectures to support larger-scale studies, more sophisticated analyses, and translation of learnings across multiple domain areas.

COVID-19 Early Treatment Fund (CETF)
Applications are accepted on a rolling basis

  • CETF is raising funds to test the most promising existing drugs in outpatient trials and helping those studies recruit patients. We are the only organization in the world that is exclusively focused on outpatient trials testing treatments immediately after infection. A scientist can apply for funding and get up to a $1M commitment in less than a week. Funding multiple shots on goal quickly is the fastest way to end the pandemic.

Robert Wood Johnson Foundation (RWJF): Pioneering Ideas – Exploring the Future to Build a Culture of Health
Proposals will be accepted on a rolling basis throughout the year

  • Pioneering Ideas: Exploring the Future to Build a Culture of Health seeks proposals that are primed to influence health equity in the future. The Foundation is interested in ideas that address any of these four areas of focus: Future of Evidence; Future of Social Interaction; Future of Food; Future of Work. RWJF welcomes proposals from scientists, anthropologists, artists, urban planners, and community leaders – anyone, anywhere who has a cutting edge idea that could alter the trajectory of health and increase opportunities for everyone in the United States to live their healthiest life possible.
  • While this RFP is focused on broader and longer-term societal trends and shifts that were evolving prior to the COVID-19 outbreak, the Foundation recognizes the unique circumstances and learning created by the COVID-19 pandemic may inform your response. It is at your discretion whether you propose a project related to the pandemic directly or indirectly.

Mozilla Open Source Support Program (MOSS) COVID-19 Solutions Fund
Applications are accepted on a rolling basis

  • Mozilla will provide awards of up to $50,000 each to open source technology projects which are responding to the COVID-19 pandemic in some way. As part of the COVID-19 Solutions Fund, we will accept applications that are hardware (e.g., an open source ventilator), software (e.g., a platform that connects hospitals with people who have 3D printers who can print parts for that open source ventilator), as well as software that solves for secondary effects of COVID-19 (e.g., a browser plugin that combats COVID related misinformation).

FastGrants – Fast Funding for COVID-19 Science
Applications accepted on a rolling basis – current on hold due to large number of application received.

  • Science funding mechanisms are too slow in normal times and may be much too slow during the COVID-19 pandemic. Fast Grants are an effort to correct this. If you are a scientist at an academic institution currently working on a COVID-19 related project and in need of funding, we invite you to apply for a Fast Grant. Fast Grants are $10k to $500k and decisions are made in under 48 hours. If we approve the grant, you’ll receive payment as quickly as your university can receive it

PCORI Funding Opportunity for COVID-19-Related Enhancements to Existing PCORI-Funded Research
Applications accepted on a rolling basis

  • PCORI seeks investigator-initiated proposals to address the COVID-19 public health crisis through enhancements of currently funded PCORI research awards. Only PCORI-funded principal investigators with active research project funding contracts are eligible to submit a proposal in response to this announcement.

Wellcome Trust – Epidemic Preparedness: COVID-19 Funding Call
Applications accepted on rolling basis

  • Applicants must be able to swiftly begin to investigate new approaches for preventing and controlling COVID-19. Proposals should focus on helping low- and middle-income countries prepare for and deal with the epidemic. Eligible applicants are researchers with a PhD or the equivalent, and significant postdoctoral research experience. These awards are open to individuals or teams of up to five members. Applicants can be based anywhere in the world (apart from mainland China). Wellcome Trust particularly encourages applications from lead applicants based in low- and middle-income countries.

Relevant Links

Additional COVID-19 Funding Opportunities

SPIN COVID-19 Links

Webinar: Proposal Writing in the Time of COVID-19 Recording and Slides from June 11, 2020